慢性乙型肝炎低水平病毒血症的研究进展  

Research progress on low-level viremia in chronic hepatitis B

作　　者：邓亚 张珊[3] 纪冬 DENG Ya;ZHANG Shan;JI Dong(The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510515,China)

机构地区：[1]南方医科大学第二临床医学院,广州510515 [2]解放军总医院第五医学中心肝病医学部肝病科,北京100039 [3]北京大学三〇二临床医学院,100039

出　　处：《传染病信息》2021年第4期342-346,共5页Infectious Disease Information

基　　金：中国人民解放军总医院课题(2019MBD-024);“十三五”国家科技重大专项(2018ZX10725-506)。

摘　　要：慢性乙型肝炎(chronic hepatitis B, CHB)是一种广泛的全球性感染性疾病,可以发展为肝硬化甚至肝细胞癌。聚乙二醇化干扰素α和核苷(酸)类似物等治疗药物可以抑制HBV,延缓CHB患者的疾病进展,但部分患者经强效低耐药药物治疗后仍不能获得有效的病毒学应答,而持续存在的低水平病毒血症可以诱发耐药、促进肝纤维化进展、增加肝细胞癌发生风险,严重影响患者预后。明确低水平病毒血症的危害,探索阐明其发生机制,从而辅助调整个体化治疗方案,是目前的研究热点及难点。本文就低水平病毒血症相关的病因、危害及治疗等方面的研究进展进行阐述,以期为该类患者的诊疗提供参考。Chronic hepatitis B(CHB) is a widespread global infectious disease that can develop into liver cirrhosis and even hepatocellular carcinoma. Therapeutic drugs such as pegylated interferon alpha and nucleo(s)tide analogs can inhibit HBV and delay the disease progression of CHB patients. However, some patients still cannot obtain an effective virological response after being treated with strong and low-drug-resistant drugs. Persistent low-level viremia can induce drug resistance, promote the progression of liver fibrosis,increase the risk of hepatocellular carcinoma and seriously affect the prognosis of patients. Clarifying the harm of low-level viremia and exploring the pathogenesis to assist in the adjustment of individualized treatment plans are current research hotspots and difficulties. This article aims to describe the research progress of low-level viremia-related etiology, harm and treatment, in order to provide reference for the diagnosis and treatment of these patients.

关 键 词：慢性乙型肝炎 低水平病毒血症 治疗 

分 类 号：R512.62[医药卫生—内科学]